Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA.
Amanda RibbandsNatalie BoytsovAbigail Lucy BaileyBoris GorshEmily LukeAnnabel LambertPublished in: Future oncology (London, England) (2023)
Aim: To explore treatment selection for relapsed/refractory multiple myeloma (RRMM), which remains complex due to heterogeneity of available treatments and lack of defined standard of care. Patients & methods: The Adelphi Real World MM Disease Specific Programme surveyed physicians in the USA and their patients with MM to collect real-world data on patterns and perceptions of MM treatment across lines of therapy (LOT). Results: Triplets were the most common regimens across each LOT. Physicians reported efficacy-related factors, health insurance coverage, and clinical guidelines as key determinants of treatment choice regardless of LOT. Patients identified better quality of life as the most important treatment benefit. Conclusion: The DSP RW data highlight drivers of RRMM treatment choice from physicians' and patients' perspectives and need for a more holistic approach to guidelines and clinical trials that encompasses patient perspectives.
Keyphrases
- end stage renal disease
- primary care
- multiple myeloma
- clinical trial
- health insurance
- ejection fraction
- chronic kidney disease
- healthcare
- peritoneal dialysis
- newly diagnosed
- palliative care
- prognostic factors
- electronic health record
- acute lymphoblastic leukemia
- acute myeloid leukemia
- big data
- replacement therapy
- deep learning
- combination therapy
- mesenchymal stem cells
- machine learning
- quality improvement
- cell therapy
- artificial intelligence
- bone marrow
- affordable care act